Browse by author
Lookup NU author(s): Professor Alan Calvert,
Dr Andrew Hall,
Professor John Lunec,
Professor Herbie Newell,
Professor Andrew Pearson,
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Thymidylate synthase (TS) expression has been characterized for a panel of eight human colorectal carcinoma and five human leukaemia cell lines, to relate differences in intrinsic TS activity, protein and mRNA levels to growth inhibition caused by continuous exposure to THYMITAQ®, a specific non-classical antifolate TS inhibitor. Although a 20-fold variation in sensitivity to THYMITAQ® was found within the colorectal cell line panel (IC50 0.12-2.7 μM, sensitivity was not related to TS activity, TS protein or TS mRNA levels. For the leukaemic cell lines, only a twofold range in sensitivity to THYMITAQ® was observed (IC50 0.87-2.3 μM), and this did not correlate with TS activity, TS protein or TS mRNA levels. Across all of the cell lines, TS activity was linearly related to TS protein levels (r2 = 0.87, P < 0.0001). However, for both the colorectal and leukaemia cell line panels, no relationship was found between TS mRNA/18S rRNA ratios and either TS activity or TS protein, consistent with the importance of post-transcriptional mechanisms in regulating TS activity. Two of the colorectal cell lines (BE and HCT116) and one of the human leukaemic cell lines (HL60), were intrinsically resistant to THYMITAQ® (IC50 > 2 μM) in the absence of TS overexpression, suggesting that, subsequent to TS inhibition, events such as DNA repair and tolerance to apoptotic stimuli are also important determinants of sensitivity to THYMITAQ®.
Author(s): Estlin, E., Balmanno, K., Calvert, A. H., Hall, A. G., Lunec, J., Newell, D. R., Pearson, A. D. J., Taylor, G. A.
Publication type: Article
Publication status: Published
Journal: British Journal of Cancer
Print publication date: 01/06/1997
ISSN (print): 0007-0920
ISSN (electronic): 1532-1827
PubMed id: 9413945